Practice changes in renal artery stenting after the CORAL trial

INTRODUCTION: Renal angioplasty emerged as an alternative for renal artery stenosis (RAS). In 2009 and 2014, two clinical trials (ASTRAL and CORAL) led to a paradigm shift in renovascular disease. Neither showed a clear benefit over best medical treatment, although there were methodological fla...

Full description

Bibliographic Details
Main Authors: Antonio Duarte, Mariana Moutinho, Alice Lopes, Gonçalo Sobrinho, Luis Mendes Pedro
Format: Article
Language:Portuguese
Published: Sociedade Portuguesa de Angiologia e Cirurgia Vascular 2023-05-01
Series:Angiologia e Cirurgia Vascular
Subjects:
Online Access:https://acvjournal.com/index.php/acv/article/view/503
_version_ 1827942271080726528
author Antonio Duarte
Mariana Moutinho
Alice Lopes
Gonçalo Sobrinho
Luis Mendes Pedro
author_facet Antonio Duarte
Mariana Moutinho
Alice Lopes
Gonçalo Sobrinho
Luis Mendes Pedro
author_sort Antonio Duarte
collection DOAJ
description INTRODUCTION: Renal angioplasty emerged as an alternative for renal artery stenosis (RAS). In 2009 and 2014, two clinical trials (ASTRAL and CORAL) led to a paradigm shift in renovascular disease. Neither showed a clear benefit over best medical treatment, although there were methodological flaws. This study aims to evaluate the impact of these trials in clinical practice. METHODS: We designed a retrospective cross-sectional study from patients submitted to renal artery angioplasty between 1999 and 2021 in a tertiary center. Patients were selected from the center’s surgical records. Diagnostic arteriograms, open interventions and renal graft failures were excluded. Patients were divided in two cohorts: a historical group from 1999 to 2013 and a contemporary cohort, from 2014 to 2021. We compared the number of angioplasties per year and patient comorbidities, preoperative lesion severity, renal function, and the number of antihypertensive drugs. RESULTS: 152 patients were included: 104 patients between 1999-2013 (7 cases per year [5-8]) and 48 patients between 2014-2021 (6.5 cases per year [4.5-7]), with no significant difference between medians (p=0.53). Patients included between 2014-2021 were taking more antihypertensive drugs (3 [2-4] vs. 2 [1-3]; p=0.001) with a worse renal function (eGFR 44,2 ± 25,9 vs. 68,6 ± 29,2; p<0.001). Comparing with the results from the CORAL trial, patients included in the whole cohort had a significantly higher degree of stenosis (84.2 ± 7.52 vs. 72.5 ± 14.6; p < 0.001) and a higher proportion of patients in stage ≥3 chronic kidney disease (56.6% vs. 49.6%; p 0.002). While there was a benefit in renal function improvement, no difference was found in blood pressure control. CONCLUSION: Renal artery angioplasties emerged as a first-choice therapy in hemodynamically significant stenoses in patients with difficult-to-control hypertension with or without renal failure. The CORAL trial in 2014, by showing no clear benefit over best medical treatment, led to a paradigm shift. Although the annual number of procedures remained unchanged, patients treated after 2014 had more severe lesions, worse preoperative renal function and blood pressure control. Further studies should assess who truly benefits from this procedure.
first_indexed 2024-03-13T09:56:56Z
format Article
id doaj.art-aeb3c12364164441a07a82d15cbda31b
institution Directory Open Access Journal
issn 1646-706X
2183-0096
language Portuguese
last_indexed 2024-03-13T09:56:56Z
publishDate 2023-05-01
publisher Sociedade Portuguesa de Angiologia e Cirurgia Vascular
record_format Article
series Angiologia e Cirurgia Vascular
spelling doaj.art-aeb3c12364164441a07a82d15cbda31b2023-05-23T20:59:58ZporSociedade Portuguesa de Angiologia e Cirurgia VascularAngiologia e Cirurgia Vascular1646-706X2183-00962023-05-0119110.48750/acv.503Practice changes in renal artery stenting after the CORAL trialAntonio Duarte0Mariana Moutinho1Alice Lopes2Gonçalo Sobrinho3Luis Mendes Pedro4Division of Vascular Surgery, Heart and Vessels Department, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Lisbon Academic Medical Centre, Lisbon PortugalDivision of Vascular Surgery, Heart and Vessels Department, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Lisbon Academic Medical Centre, Lisbon PortugalDivision of Vascular Surgery, Heart and Vessels Department, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Lisbon Academic Medical Centre, Lisbon PortugalDivision of Vascular Surgery, Heart and Vessels Department, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Lisbon Academic Medical Centre, Lisbon Portugal; Faculty of Medicine, University of Lisbon, PortugalDivision of Vascular Surgery, Heart and Vessels Department, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Lisbon Academic Medical Centre, Lisbon Portugal; Faculty of Medicine, University of Lisbon, Portugal INTRODUCTION: Renal angioplasty emerged as an alternative for renal artery stenosis (RAS). In 2009 and 2014, two clinical trials (ASTRAL and CORAL) led to a paradigm shift in renovascular disease. Neither showed a clear benefit over best medical treatment, although there were methodological flaws. This study aims to evaluate the impact of these trials in clinical practice. METHODS: We designed a retrospective cross-sectional study from patients submitted to renal artery angioplasty between 1999 and 2021 in a tertiary center. Patients were selected from the center’s surgical records. Diagnostic arteriograms, open interventions and renal graft failures were excluded. Patients were divided in two cohorts: a historical group from 1999 to 2013 and a contemporary cohort, from 2014 to 2021. We compared the number of angioplasties per year and patient comorbidities, preoperative lesion severity, renal function, and the number of antihypertensive drugs. RESULTS: 152 patients were included: 104 patients between 1999-2013 (7 cases per year [5-8]) and 48 patients between 2014-2021 (6.5 cases per year [4.5-7]), with no significant difference between medians (p=0.53). Patients included between 2014-2021 were taking more antihypertensive drugs (3 [2-4] vs. 2 [1-3]; p=0.001) with a worse renal function (eGFR 44,2 ± 25,9 vs. 68,6 ± 29,2; p<0.001). Comparing with the results from the CORAL trial, patients included in the whole cohort had a significantly higher degree of stenosis (84.2 ± 7.52 vs. 72.5 ± 14.6; p < 0.001) and a higher proportion of patients in stage ≥3 chronic kidney disease (56.6% vs. 49.6%; p 0.002). While there was a benefit in renal function improvement, no difference was found in blood pressure control. CONCLUSION: Renal artery angioplasties emerged as a first-choice therapy in hemodynamically significant stenoses in patients with difficult-to-control hypertension with or without renal failure. The CORAL trial in 2014, by showing no clear benefit over best medical treatment, led to a paradigm shift. Although the annual number of procedures remained unchanged, patients treated after 2014 had more severe lesions, worse preoperative renal function and blood pressure control. Further studies should assess who truly benefits from this procedure. https://acvjournal.com/index.php/acv/article/view/503renal artery stenosisrenovascular hypertensionischemic nephropathypercutaneous angioplastychronic kidney disease
spellingShingle Antonio Duarte
Mariana Moutinho
Alice Lopes
Gonçalo Sobrinho
Luis Mendes Pedro
Practice changes in renal artery stenting after the CORAL trial
Angiologia e Cirurgia Vascular
renal artery stenosis
renovascular hypertension
ischemic nephropathy
percutaneous angioplasty
chronic kidney disease
title Practice changes in renal artery stenting after the CORAL trial
title_full Practice changes in renal artery stenting after the CORAL trial
title_fullStr Practice changes in renal artery stenting after the CORAL trial
title_full_unstemmed Practice changes in renal artery stenting after the CORAL trial
title_short Practice changes in renal artery stenting after the CORAL trial
title_sort practice changes in renal artery stenting after the coral trial
topic renal artery stenosis
renovascular hypertension
ischemic nephropathy
percutaneous angioplasty
chronic kidney disease
url https://acvjournal.com/index.php/acv/article/view/503
work_keys_str_mv AT antonioduarte practicechangesinrenalarterystentingafterthecoraltrial
AT marianamoutinho practicechangesinrenalarterystentingafterthecoraltrial
AT alicelopes practicechangesinrenalarterystentingafterthecoraltrial
AT goncalosobrinho practicechangesinrenalarterystentingafterthecoraltrial
AT luismendespedro practicechangesinrenalarterystentingafterthecoraltrial